The Greek Version of the Mild Behavioral Impairment Checklist (MBI-C): Psychometric Properties in Mild Cognitive Impairment Due to Alzheimer’s Disease DOI Creative Commons
Efthalia Angelopoulou, Evangelia Stanitsa,

Maria Hatzopoulou

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(5), С. 462 - 462

Опубликована: Апрель 27, 2025

Mild behavioral impairment (MBI) is an early marker of Alzheimer's disease (AD) and other neurodegenerative diseases, often preceding cognitive decline. The MBI Checklist (MBI-C) a 34-item tool designed to detect MBI. This study aimed assess the psychometric properties Greek version MBI-C its ability differentiate patients with mild due AD (MCI-AD) from cognitively unimpaired older adults (healthy participants, HPs). A total 181 participants (104 MCI-AD, 77 HPs) were recruited Third Age Day Care Center IASIS (2019-2023), accompanied by close informant. Participants underwent neuropsychological assessment [Mini-Mental State Examination (MMSE), Addenbrooke's Cognitive Examination-Revised (ACE-R)], informants completed MBI-C. Internal consistency was evaluated using Cronbach's α known-group validity assessed via comparing between MCI-AD HPs groups. Diagnostic accuracy determined receiver operating characteristic (ROC) analysis. showed excellent internal (Cronbach's = 0.899). Among domains, impulse dyscontrol demonstrated highest reliability (α 0.901), whereas decreased motivation 0.564) abnormal perception/thought content 0.617) exhibited lower reliability. domain scores significantly higher in than (p < 0.001). area under curve (AUC) 0.871 (optimal cutoff 9.5), indicating diagnostic performance. Overall, has strong for MCI-AD. Sociocultural factors might influence symptom identification reporting, particularly domains content. Future research should investigate predictive value dementia conversion applicability populations, including individuals subjective decline non-AD causes MCI.

Язык: Английский

Blood-based biomarkers in mild behavioral impairment: an updated overview DOI Creative Commons
Efthalia Angelopoulou,

Xenia Androni,

Chiara Villa

и другие.

Frontiers in Neurology, Год журнала: 2025, Номер 16

Опубликована: Фев. 6, 2025

Identifying individuals at-risk for dementia is one of the critical objectives current research efforts, highlighting need simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by emergence persistent neuropsychiatric manifestations in older adults, has attracted increasing attention as a potential early indicator cognitive decline dementia. A growing number studies have recently begun to explore relationship between MBI several blood-based biomarkers associated with Alzheimer's disease (AD) pathology, neurodegeneration, well systemic metabolic inflammatory dysregulation. In this context, been lower plasma Aβ42/Αβ40 ratio, higher phosphorylated tau at threonine 181 (p-tau181), increased neurofilament light chain (NfL) levels, disturbances markers, including homocysteine, insulin ferritin, suggesting multifaceted neurobiological basis syndrome. These findings offer insights into underlying pathophysiology MBI, connection symptoms progression AD. narrative review, we aim summarize critically discuss emerging literature evidence linking biomarkers, hoping shed more on MBI's pathophysiology, its AD-related neurobiology, practical utility predicting impairment, guiding interventions managing risk

Язык: Английский

Процитировано

2
The Advancements of Marine Natural Products in the Treatment of Alzheimer’s Disease: A Study Based on Cell and Animal Experiments DOI Creative Commons
Chunbo Jia, Jian Chai,

Shenyun Zhang

и другие.

Marine Drugs, Год журнала: 2025, Номер 23(3), С. 91 - 91

Опубликована: Фев. 20, 2025

As life expectancy rises and the aging population grows, Alzheimer’s disease (AD) has become a significant global health concern. AD is complex neurodegenerative disorder with an unclear etiology. Current hypotheses primarily focus on β-amyloid (Aβ) aggregation, tau protein hyperphosphorylation, neuroinflammation as key pathological processes. Given limited efficacy of existing therapeutic strategies, there urgent need to explore novel treatment options. Marine natural products have garnered attention due their unique chemical structures diverse bioactivities, demonstrating potential for multi-target interventions in AD. This review systematically summarizes roles marine-derived compounds, including polysaccharides, carotenoids, polyphenols, modulating Aβ mitigating pathology, regulating gut–brain axis dysfunction. Furthermore, challenges current research are discussed, emphasis improving blood–brain barrier permeability optimizing drug delivery systems facilitate clinical translation.

Язык: Английский

Процитировано

1
The Greek Version of the Mild Behavioral Impairment Checklist (MBI-C): Psychometric Properties in Mild Cognitive Impairment Due to Alzheimer’s Disease DOI Creative Commons
Efthalia Angelopoulou, Evangelia Stanitsa,

Maria Hatzopoulou

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(5), С. 462 - 462

Опубликована: Апрель 27, 2025

Mild behavioral impairment (MBI) is an early marker of Alzheimer's disease (AD) and other neurodegenerative diseases, often preceding cognitive decline. The MBI Checklist (MBI-C) a 34-item tool designed to detect MBI. This study aimed assess the psychometric properties Greek version MBI-C its ability differentiate patients with mild due AD (MCI-AD) from cognitively unimpaired older adults (healthy participants, HPs). A total 181 participants (104 MCI-AD, 77 HPs) were recruited Third Age Day Care Center IASIS (2019-2023), accompanied by close informant. Participants underwent neuropsychological assessment [Mini-Mental State Examination (MMSE), Addenbrooke's Cognitive Examination-Revised (ACE-R)], informants completed MBI-C. Internal consistency was evaluated using Cronbach's α known-group validity assessed via comparing between MCI-AD HPs groups. Diagnostic accuracy determined receiver operating characteristic (ROC) analysis. showed excellent internal (Cronbach's = 0.899). Among domains, impulse dyscontrol demonstrated highest reliability (α 0.901), whereas decreased motivation 0.564) abnormal perception/thought content 0.617) exhibited lower reliability. domain scores significantly higher in than (p < 0.001). area under curve (AUC) 0.871 (optimal cutoff 9.5), indicating diagnostic performance. Overall, has strong for MCI-AD. Sociocultural factors might influence symptom identification reporting, particularly domains content. Future research should investigate predictive value dementia conversion applicability populations, including individuals subjective decline non-AD causes MCI.

Язык: Английский

Процитировано

0